Suppr超能文献

新孕激素和选择性孕激素受体调节剂治疗子宫内膜异位症的疗效、安全性和复发:小鼠比较研究。

Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice.

机构信息

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, c/o 1st Floor, Special Block E, Prince of Wales Hospital, Shatin, Hong Kong.

Reproduction and Development Laboratory, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong.

出版信息

Reprod Biol Endocrinol. 2018 Apr 3;16(1):32. doi: 10.1186/s12958-018-0347-9.

Abstract

BACKGROUND

Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied.

METHODS

In order to compare therapeutic, side effects and therapeutic actions of Esmya, Duphaston and Dienogest in endometriosis. Experimental endometriosis was induced by either intraperitoneal or subcutaneous mouse endometrium transplantation. Lesion size, weight and histology at the end of intervention were compared. Expression of related markers in the endometriotic lesions were examined. Body, uterus and ovary weights, endometrial glands and thickness (ETI), and follicle count were measured. For recurrent study, lesion growth before and after intervention was monitored.

RESULTS

After Esmya, Duphaston, Dienogest treatment, lesion size and weight were significantly decreased. Proliferation Pcna expression was significantly decreased in all groups, but proliferation cells were significantly decreased only in Duphaston group. Apoptosis Mapk1 expression and TUNEL-positive cells were significantly increased in Duphaston group. Adhesion Mmp2 and Itgavβ3 expression were significantly increased in Esmya group. Plau, Hif1α and Vegfa expression, peritoneal fluid PGE2 levels, and ERα and ERβ expression were not affected; while PR expression was significantly lower in all groups. Endometrial gland count in uterus was significantly increased in Dienogest group, ETI was significantly decreased in Duphaston group, and AFC were significantly increased in Esmya group. Upon treatment cessation, lesion growth rebound quickly in Dienogest and Duphaston groups, but slowly in Esmya group.

CONCLUSION

Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya.

摘要

背景

目前针对子宫内膜异位症的医学治疗方法非常有限。孕激素和选择性孕激素受体调节剂(SPRMs)已被开发出来,但它们在子宫内膜异位症中的疗效、安全性、作用机制和复发情况尚未得到充分研究。

方法

为了比较 Esmya、Duphaston 和 Dienogest 在子宫内膜异位症中的治疗效果、副作用和治疗作用,通过腹腔内或皮下移植小鼠子宫内膜的方法诱导实验性子宫内膜异位症。在干预结束时比较病灶大小、重量和组织学变化。检测子宫内膜异位症病灶中相关标志物的表达。测量体质量、子宫和卵巢重量、子宫内膜腺体和厚度(ETI)以及卵泡计数。对于复发研究,监测干预前后病灶的生长情况。

结果

在 Esmya、Duphaston 和 Dienogest 治疗后,病灶大小和重量均显著减小。增殖标志物 Pcna 的表达在所有组中均显著降低,但增殖细胞仅在 Duphaston 组中显著减少。凋亡标志物 Mapk1 的表达和 TUNEL 阳性细胞在 Duphaston 组中显著增加。黏附标志物 Mmp2 和 Itgavβ3 的表达在 Esmya 组中显著增加。Plau、Hif1α 和 Vegfa 的表达、腹腔液 PGE2 水平以及 ERα 和 ERβ 的表达不受影响;而 PR 的表达在所有组中均显著降低。子宫内子宫内膜腺体计数在 Dienogest 组中显著增加,Duphaston 组中 ETI 显著降低,Esmya 组中 AFC 显著增加。停药后,Dienogest 和 Duphaston 组病灶快速反弹生长,而 Esmya 组则缓慢反弹生长。

结论

Esmya、Duphaston 和 Dienogest 是针对增殖、凋亡和黏附的有效抗子宫内膜异位症药物。Esmya、Duphaston 和 Dienogest 均具有良好的耐受性,尽管 Dienogest 组出现子宫内膜腺体增生、Duphaston 组出现子宫内膜萎缩、Esmya 组出现卵泡堆积。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5446/5883298/45d05aaade1a/12958_2018_347_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验